|
1
|
Sanz MA, Montesinos P, Rayon C, Holowiecka
A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera
JM, et al: Risk-Adapted treatment of acute promyelocytic leukemia
based on all-trans retinoic acid and anthracycline with addition of
cytarabine in consolidation therapy for highrisk patients: Further
improvements in treatment outcome. Blood. 115:5137–5146.
2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Lo-Coco F, GAvvisati G, Vignetti M, Thiede
C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona
E, et al: Retinoic acid and arsenic trioxide for acute
promyelocytic leukemia. N Engl J Med. 369:111–112. 2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tallman MS, Wang ES and Altman JK: Acute
Myeloid Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines
in Oncology, National Comprehensive Cancer Network.
|
|
4
|
Mandelli F, Diverio D, Avvisati G, Luciano
A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni
G, et al: Molecular remission in PML/RAR alpha-positive acute
promyelocytic leukemia by combined all-trans retinoic acid and
idarubicin (AIDA) therapy. Gruppo italiano-malattie ematologiche
maligne dell'Adulto and associazione Italiana di ematologia ed
oncologia pediatrica cooperative groups. Blood. 90:1014–1021.
1997.PubMed/NCBI
|
|
5
|
Sanz MA, Martin G, Rayon C, Esteve J,
González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol MJ,
González JD, et al: A modified AIDA protocol with
anthracycline-based consolidation results in high antileukemic
efficacy and reduced toxicity in newly diagnosed
PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
Blood. 94:3015–3021. 1999.PubMed/NCBI
|
|
6
|
Fenaux P, Le Deley MC, Castaigne S,
Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT
and Bowen D: Effect of all transretinoic acid in newly diagnosed
acute promyelocytic leukemia. Results of a multicenter randomized
trial. European APL 91 group. Blood. 82:3241–3249. 1993.PubMed/NCBI
|
|
7
|
Zhixiang S, et al: Chinese guidelines for
diagnosis and treatment of acute promyelocytic leukemia. Zhonghua
Xue Ye Xue Za Zhi. 37:179–183. 2016.
|
|
8
|
Xu F, Yin CX, Wang CL, Ding BJ, Zhong QX,
Jiang XJ, Jiang L, Wang ZX and Meng FY: Influence of initiation
time and white blood cell count on the efficacy of cytotoxic agents
in acute promyelocytic leukemia during induction treatment. Biomed
Rep. 39:227–232. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sanz MA, Lo Coco F, Martin G, Avvisati G,
Rayón C, Barbui T, Díaz-Mediavilla J, Fioritoni G, González JD,
Liso V, et al: Definition of relapse risk and role of
nonanthracycline drugs for consolidation in patients with acute
promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA
cooperative groups. Blood. 96:1247–1253. 2000.PubMed/NCBI
|
|
10
|
Common Terminology Criteria for Adverse
Events, Version 4.03, DCTD,NCI, NIH,DHHS. 14 June 2010.
|
|
11
|
Frankel SR, Eardley A, Lauwers G, Weiss M
and Warrell RP Jr: The ‘retinoic acid syndrome’ in acute
promyelocytic leukemia. Ann Intern Med. 117:292–296.
1992.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: Revised recommendations of the international working
group for diagnosis, standardization of response criteria,
treatment outcomes, and reporting standards for therapeutic trials
in acute myeloid leukemia. J Clin Oncol. 21:4642–4649.
2003.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
14
|
Sanz MA, Fenaux P, Tallman MS, Estey EH,
Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ,
et al: Management of acute promyelocytic leukemia: Updated
recommendations from an expert panel of the European leukemia. Net
Blood. 133:1630–1643. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhang X, Zhang H, Chen L, Wang M, Xi J,
Liu X, Xie M, Li D, Gulati ES, Gong S and Wang H: Arsenic trioxide
and all-trans retinoic acid(ATRA)treatment for acute promyelocytic
leukemia in all risk groups: Study protocol for a randomized
controlled trial. Trials. 19(476)2018.PubMed/NCBI View Article : Google Scholar
|
